臨床試験セクタースコアカードの世界市場：2022年第1四半期

当レポートでは、世界の臨床試験セクタースコアカード市場を調査しており、概要、動向、および主要企業の分析など、包括的な情報を提供しています。

目次

目次

• エグゼクティブサマリー
• イントロダクション
• 製薬テーママップ
• 臨床試験スコアカード：2022年第1四半期の主要最新情報
• 企業スクリーン
• テーマ別スクリーン
• 評価スクリーン
• テーマ別調査手法
• ファーマスコアの生成方法
• 関連レポート
• 著者について
• GlobalDataについて

Artificial Intelligence, Virtual Care, and Blockchain Saw Activity in Q1 2022. Many companies included in the Clinical Trials scorecard have announced partnerships in the artificial intelligence (AI) space since December 2021. Pfizer announced partnerships in drug discovery and disease severity scoring, while Thermo Fisher Scientific announced that it was partnering with Medidata Acorn AI to optimize clinical trials. Merck KGaA is collaborating with Unlearn.AI to accelerate late-stage trials using AI-based digital twins. In virtual care, Takeda posted several jobs relating to virtual trials and initiated trials with virtual components in Q1 2022, and AstraZeneca, Novo Nordisk, and Otsuka were active in digital health deals. Takeda posted several jobs relating to blockchain in Q1 2022, and Dr. Reddy's is partnering with academia to build a new blockchain solution.

Companies Were Also Active in ESG Initiatives, Driven in Part By the Ukraine Crisis. While there were no significant changes to Environmental, Social, and Governance (ESG) scores in Q1 2022, several interesting events occurred. Samsung Bioepis released its first annual sustainability report, and in March 2022 Zydus Cadila announced that it was to acquire a stake in AMP Energy Green Nine, a move that is in line with its commitment to enhance its use of renewable power. AstraZeneca announced that it was developing inhalers that use a more environmentally friendly propellant, HFO-1234ze, and it was also reported that AstraZeneca China employees were being investigated for suspected medical insurance fraud. Many pharma companies have responded to the Ukraine crisis by donating essentials medicines, medical supplies, and financial support to non-governmental organizations (NGOs).

Scope

• GlobalData's Clinical Trials Thematic Scorecard report provides a top-down, comprehensive future outlook for key players in the clinical trial sector over the next two to four years.
• These themes are Virtual Care, Rare Disease, Orphan Designated Drugs, Strategic Alliances, Real-world Evidence, AI, ESG, Cybersecurity, Cloud Computing, and Blockchain.
• The scorecard includes 53 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).
• It is important to note that this scorecard is not an assessment of current performance of a company in a theme, but a view of future performance based on current levels of activity and investment.
• The methodology section contains information on what data sources were used to generate the thematic scores for each company.
• The scorecard is live on the PIC and will be updated quarterly.

Reasons to Buy

• Identify the key clinical trial themes for the next 2-4 years and learn how they will impact the market.
• Understand which key themes should be addressed to drive share price.
• Understand which companies are best positioned for success within critical themes and why.
• Learn which companies have underinvested in key themes and are most vulnerable to disruption.
• Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
• Help identify future winners and losers in drug development to inform partnership strategies.

Table of Contents

Table of Contents

• Executive Summary
• Introduction
• Pharma Theme Map
• Clinical Trials Scorecard: Key Q1 2022 Updates
• Company Screen
• Thematic Screen
• Valuation Screen
• Our Thematic Research Methodology
• How Our Pharma Scores Are Generated
• Related Reports
• About the Authors
• About GlobalData